clinical trial · NCT07372287
A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 230
Moderate to Severe AsthmaCM326Placebo
brief summary
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.
started
Jan 26, 2026
primary completion
Dec 31, 2028
completion
Mar 31, 2029
last updated
Jan 28, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol